John Kuruvilla, MD on the Specific of the Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO

John Kuruvilla, MD on the Specific of the Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO

User Photo
Cancer-News

4 months
32 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)
Up Next Autoplay